Antoine Beret

Graduated from Ecole Nationale des Ponts et Chaussées, Ecole Polytechnique. Founder of several successful French biotechnological companies. He Founded Immunotech and served as its Chief Executive Officer until 1998 when Immunotech was acquired by Beckman-Coulter.  From 1999 to 2008 Mr. Beret served as the Chief Executive Officer and President of Trophos. Trophos developped the Olesoxime for Infantile spinal Amyotrophy until Phase 2/3 until the company was recently acquired by Roche for 700 ME.

 Bob Duggan

is the founder and principal of a venture capital and securities investment firm, Robert W. Duggan & Associates. He has served as an adviser, investor and director of numerous small and large businesses with an emphasis on computer technologies, medical products, consumer retail goods and outdoor media communication. Three of his venture capital companies have become publicly traded securities on either the New York Stock Exchange or NASDAQ. Two additional ventures have been sold to Fortune 500 companies. His most recent position was chief executive officer at Pharmacyclics Inc., from 2009 until 2015. Mr. Duggan also served as chief executive officer of Computer Motion, Inc. from 1997-2003.Duggan studied economics at the University of California, Santa Barbara and business management at UCLA. In 2015, Mr Duggan was recognized as one of the top 20 most influential executives in the biopharmaceutical field. In 2002, he received the 'Legion d'honneur' from the French President.

 Vincent Fert, PhD

co-founded HalioDx SAS in 2014 and serves as its Chief Executive Officer, President and Chairman of the Board. Mr. Fert co-founded Qiagen Marseille Société Anonyme in 1999 and serves as its Chief Executive Officer, Managing Director and President. Mr. Fert served an executive position at Immunotech, one of the first successful French biotech companies involved in monoclonal antibodies and diagnostic

Philippe Halfon,  MD, PharmD, PhD, President and founder

 is the founder of several biotechnology companies focusing on antiviral drug discovery and development, including ACTgene, Alphabio, and GenosciencePharma.  He completed training in Oncogenetic and continues to have a consultation in oncogenetic and infectious Diseases in the European Hospital. He was recently appointed as Associate Professor in Paris Medical College.

 Chaim Hurvitz (Non Members Advisor)

established CH-health, a private venture capitalfirm. He currently serves as the CEO, a position he has held since May 2011. Mr. Hurvitz was a member of Teva’s board of directors from 2010 to July 2014. He has been the chairman of Galmed Pharmaceuticals’ board of directors since 2011 and a member in UroGen Pharma Ltd.Previously, he was a member of the senior management team of Teva Pharmaceuticals Industries Ltd., serving as the president of Teva International Group from 2002 until 2010, as president and CEO of Teva Pharmaceuticals Europe from 1992 to 1999 and as vice president — Israeli pharmaceutical sales from 1999 until 2002.He is a member of the presidency board of the Manufacturers Association of Israel, , chairing its pharmaceutical branch. Mr. Hurvitz holds a Bachelor of Arts degree in political science and economics from Tel Aviv University, which was awarded in 1985.

Manmeet Singh Soni

is the former Chief Financial Officer and Treasurer at Pharmacyclics, Inc. where he worked from 2012 to 2015 in various roles in finance, accounting, business development, human resources and commercial operations. He played a vital role in Pharmacyclics' $21 billion (€18.9Bn) acquisition by Abbvie. Previously, he worked at ZELTIQ Aesthetics Inc. where he served as controller, senior director of finance responsible for accounting, SEC and treasury functions. Prior to ZELTIQ, he worked at PricewaterhouseCoopers (PwC) in the Life Science and Venture Capital Group providing audit and advisory services to various public and privately held companies in the pharmaceutical and biotechnology industry. He graduated from Hansraj College at Delhi University in India. He is a certified public accountant, licensed in the state of California and a chartered accountant from India.

 Maky Zanganeh, DDS, MS, MBA

was the chief operating officer of Pharmacyclics, Inc. from 2012 to 2015. She also served as the company’s chief of staff and chief business officer from August 2008 to July 2012. Prior to joining Pharmacyclics, from 2007 to 2008, Dr. Zanganeh served as president director general for the French government initiative bio-cluster project, establishing regional alliances and developing small life science businesses. From 2003 to 2008 Dr. Zanganeh also served as vice president of business development for Robert W. Duggan & Associates. Between 1998 and 2002 she worked for Computer Motion Inc., the world initiator of medical robotics, as the president director general for Europe, the Middle East and Africa and, from 2002 to 2003, as worldwide vice president of training and education. Dr. Zanganeh received a DDS degree from Louis Pasteur University in Strasbourg, France and an MBA from Schiller International University in France. In 2013, she was recognized as among the top 10 biotech executive women of the year and was nominated as the entrepreneur of the year in Northern California by EY. 

Jean Marc Feryn, PharmD

is the co-founder of  Alphabio, ACT gene and GenosciencePharma




       Chalom Sayada, MD, PharmD, PhD

is the Co-founder and CEO of Advanced Biological Laboratories SA, Chalom Sayada previously served as CEO of Sequoia Pharmaceuticals Inc (2004), President and CEO of ActivBiotics Inc. (2000-2003), Vice President at Visible Genetics (1998-2000),. Chalom has extensive experience gained from his positions in early and clinical development at pharmaceutical and diagnostics companies in the United States and in Europe.